CFRX - コントラフェクト (ContraFect Corporation) コントラフェクト

 CFRXのチャート


 CFRXの企業情報

symbol CFRx
会社名 ContraFect Corp (コントラフェクト)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 コントラフェックト(ContraFect Corporation)はバイオテクノロジー企業である。同社は、治療用タンパク質、入院を必要とする生命を脅かす薬剤耐性感染症のための抗体製品の発見及び開発に焦点を当てる。同社は、細菌やウイルスの保存領域(変異を起こしにくい領域)を標的とするリジンとモノクローナル抗体のプラットフォームからの治療薬候補を使用し、薬剤耐性感染症に対処する。同社の製品候補は、黄色ブドウ球菌菌血症の治療のためのリジン「CF-301」、生命を脅かす季節性及びパンデミック・インフルエンザの治療のためのmAbの組み合わせ「CF-404」を含む。「CF-301」と「CF-302」は、黄色ブドウ球菌感染症に対して強力な活性を持つバクテリオファージリシンである。   コントラフェクトは治療用タンパク質と抗体の開発に焦点を置く米国のバイオ医薬品会社。細菌細胞壁を消化するリシン(タンパク質構成アミノ酸)とモノクロ―ナ抗体を開発。黄色ブドウ球菌菌血症、肺炎、骨髄炎、感染性心内膜炎の治療用リシンCF301の治験を行う。また、インフルエンザに対するモノクロ―ナ抗体の開発を行う。  
本社所在地 28 Wells Avenue Third Floor Yonkers NY 10701 USA
代表者氏名 Steven C. Gilman スティーブンC.ギルマン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 914-207-2300
設立年月日 39508
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数
url www.contrafect.com
nasdaq_url https://www.nasdaq.com/symbol/cfrx
adr_tso
EBITDA EBITDA(百万ドル) -28.45300
終値(lastsale) 1.85
時価総額(marketcap) 146907678.6
時価総額 時価総額(百万ドル) 149.29000
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 115.99598
当期純利益 当期純利益(百万ドル) -45.57498
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ContraFect Corp revenues was not reported. Net loss increased from $9.2M to $39.2M. Higher net loss reflects Change in fair value of warrant liabilit decrease from $3.1M (income) to $25.1M (expense) General and administrative increase of 1% to $4.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.22 to -$0.53.

 CFRXのテクニカル分析


 CFRXのニュース

   Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday  2021/03/12 16:32:53 Benzinga
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX ), Evoke Pharma, Inc. (NASDAQ: EVOK ), Altimmune, Inc. (NASDAQ: ALT ) and Novavax, Inc. (NASDAQ: NVAX ). Here's why the stocks are moving. ContraFect Bags BARDA Funding: ContraFect, a biotech focused on developing treatments for antibiotic-resistant infections, said late Thursday BARDA has awarded $86.8 million in funding for supporting the pivotal late-stage study of exebacase as a treatment option for blood stream infection as well as infection of the heart's inner lining caused by the staphylococcus aureus bacteria. If the Phase 3 data proves to be positive, BARDA could extend additional financial assistance upon achievement of key milestones to advance the investigational asset through FDA approval and completion of post-approval commitments. Evoke Plunges On Gimoti Disappointment: Evoke was pulling back sharply following the … Full story available on Benzinga.com
   The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs  2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.
   Critical Analysis: NextCure (NASDAQ:NXTC) vs. ContraFect (NASDAQ:CFRX)  2020/10/23 07:26:46 Dakota Financial News
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares NextCure and ContraFect’s top-line revenue, earnings per share and valuation. Gross […]
   NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) Head to Head Review  2020/10/20 02:24:48 Daily Political
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for NextCure and ContraFect, as […]
   ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants  2020/05/21 20:09:28 GlobeNewswire
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and…
   Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday  2021/03/12 16:32:53 Benzinga
Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX ), Evoke Pharma, Inc. (NASDAQ: EVOK ), Altimmune, Inc. (NASDAQ: ALT ) and Novavax, Inc. (NASDAQ: NVAX ). Here's why the stocks are moving. ContraFect Bags BARDA Funding: ContraFect, a biotech focused on developing treatments for antibiotic-resistant infections, said late Thursday BARDA has awarded $86.8 million in funding for supporting the pivotal late-stage study of exebacase as a treatment option for blood stream infection as well as infection of the heart's inner lining caused by the staphylococcus aureus bacteria. If the Phase 3 data proves to be positive, BARDA could extend additional financial assistance upon achievement of key milestones to advance the investigational asset through FDA approval and completion of post-approval commitments. Evoke Plunges On Gimoti Disappointment: Evoke was pulling back sharply following the … Full story available on Benzinga.com
   The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs  2021/03/12 12:36:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 11) Affimed N.V. (NASDAQ: AFMD ) AngioDynamics, Inc. (NASDAQ: ANGO ) Apyx Medical Corporation (NASDAQ: APYX ) AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) Axonics Modulation Technologies, Inc. (NASDAQ: AXNX ) BioAtla, Inc. (NASDAQ: BCAB ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ) Entera Bio Ltd. (NASDAQ: ENTX ) ( announced positive Phase 2 biomarker data for osteoarthritis drug) Harvard Bioscience, Inc. (NASDAQ: HBIO ) IDEAYA Biosciences, Inc. (NASDAQ: IDYA ) Inari Medical, Inc. (NASDAQ: NARI ) Jounce Therapeutics, Inc. (NASDAQ: JNCE ) Longeveron Inc. (NASDAQ: LGVN ) (announced FDA granting expanded access approval for its investigational cell therapy Lomecel-B to a pediatric patient with hypoplastic left heart syndrome) Magenta Therapeutics, Inc. (NASDAQ: MGTA ) Nuvation Bio Inc. (NASDAQ: NUVB )(announced orphan drug designation for NUV-422 in treating malignant gliomas) Renalytix AI plc (NASDAQ: RNLX ) Sol-Gel Technologies Ltd. (NASDAQ: SLGL ) Surmodics, Inc. (NASDAQ: SRDX ) Verrica Pharmaceuticals Inc. (NASDAQ: VRCA ) Down In The Dumps None of the NYSE- and Nasdaq-listed biotech/diagnostic shares hit 52-week lows Thursday.
   Critical Analysis: NextCure (NASDAQ:NXTC) vs. ContraFect (NASDAQ:CFRX)  2020/10/23 07:26:46 Dakota Financial News
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares NextCure and ContraFect’s top-line revenue, earnings per share and valuation. Gross […]
   NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) Head to Head Review  2020/10/20 02:24:48 Daily Political
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for NextCure and ContraFect, as […]
   ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants  2020/05/21 20:09:28 GlobeNewswire
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and…
   Critical Analysis: NextCure (NASDAQ:NXTC) vs. ContraFect (NASDAQ:CFRX)  2020/10/23 07:26:46 Dakota Financial News
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares NextCure and ContraFect’s top-line revenue, earnings per share and valuation. Gross […]
   NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) Head to Head Review  2020/10/20 02:24:48 Daily Political
NextCure (NASDAQ:NXTC) and ContraFect (NASDAQ:CFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a summary of current ratings and price targets for NextCure and ContraFect, as […]
   ContraFect Corporation Announces Proposed Public Offering of Common Stock and Warrants  2020/05/21 20:09:28 GlobeNewswire
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and…
   Contrafect EPS in-line  2019/11/12 12:19:42 Seeking Alpha
Contrafect (CFRX): Q3 GAAP EPS of -$0.07 in-line. Cash, cash equivalents and marketable securities of $10.5M Press Release
   The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation  2019/08/30 12:28:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ) NextCure Inc (NASDAQ: NXTC ) Radius Health Inc (NASDAQ: RDUS ) ResMed Inc. (NYSE: RMD ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks that hit 52-week lows on Aug. 30.) ContraFect Corp (NASDAQ: CFRX ) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Rubius Therapeutics Inc (NASDAQ: RUBY ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Genmab-Novartis' Multiple Sclerosis Drug Found Superior To Sanofi's GENMAB A/S/S ADR (NASDAQ: GMAB ), which recently listed its shares in the U.S., said Novartis AG (NYSE: NVS ), its partner in the development of atumumab, has reported positive results … Full story available on Benzinga.com

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 コントラフェクト CFRX ContraFect Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)